ATE189211T1 - Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten - Google Patents

Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten

Info

Publication number
ATE189211T1
ATE189211T1 AT95922924T AT95922924T ATE189211T1 AT E189211 T1 ATE189211 T1 AT E189211T1 AT 95922924 T AT95922924 T AT 95922924T AT 95922924 T AT95922924 T AT 95922924T AT E189211 T1 ATE189211 T1 AT E189211T1
Authority
AT
Austria
Prior art keywords
compositions
methods
diseases caused
mast cells
treating diseases
Prior art date
Application number
AT95922924T
Other languages
English (en)
Inventor
Robert T Lum
Heinz W Gschwend
Barr E Bauer
Elaine Kuo
Ken Rice
Original Assignee
Axys Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc filed Critical Axys Pharm Inc
Application granted granted Critical
Publication of ATE189211T1 publication Critical patent/ATE189211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Control Of Positive-Displacement Pumps (AREA)
AT95922924T 1994-06-01 1995-05-31 Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten ATE189211T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25209994A 1994-06-01 1994-06-01
PCT/US1995/006926 WO1995032945A1 (en) 1994-06-01 1995-05-31 Compositions and methods for treating mast-cell mediated conditions

Publications (1)

Publication Number Publication Date
ATE189211T1 true ATE189211T1 (de) 2000-02-15

Family

ID=22954603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95922924T ATE189211T1 (de) 1994-06-01 1995-05-31 Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten

Country Status (7)

Country Link
US (1) US5656660A (de)
EP (1) EP0763016B1 (de)
JP (1) JPH10501238A (de)
AT (1) ATE189211T1 (de)
AU (1) AU2764495A (de)
DE (1) DE69514798D1 (de)
WO (1) WO1995032945A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK37997A3 (en) * 1994-09-23 1998-12-02 Arris Pharm Corp Compositions and methods for treating mast-cell inflammatory condition
AU2629795A (en) * 1994-12-12 1996-07-03 Chugai Seiyaku Kabushiki Kaisha Aniline derivative having the effect of inhibiting nitrogen monoxide synthase
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
EP0934293A1 (de) * 1996-07-30 1999-08-11 Arris Pharmaceutical Corporation Verbindungen und präparate für eine behandelung von krankheiten die mit tryptaseaktivität zusammenhangen
IT1283782B1 (it) * 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
AU8997498A (en) * 1997-09-05 1999-03-29 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitor
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
AU1176299A (en) * 1997-11-26 1999-06-15 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitors comprising heterocyclic amide compounds
ES2233025T3 (es) * 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agente inhibidores de la triptasa.
US6613769B1 (en) * 1998-02-06 2003-09-02 Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. Tryptase inhibitors
JP2003524598A (ja) * 1998-09-04 2003-08-19 アルタナ ファルマ アクチエンゲゼルシャフト 新規ピラノセン
WO2000056306A1 (en) * 1999-03-19 2000-09-28 Knoll Gmbh Treatment of osteoarthritis
DE19940389A1 (de) * 1999-08-25 2001-03-01 Wilex Biotechnology Gmbh Selektive Inhibitoren des Urokinase-Plasminogen Aktivators
US6960588B1 (en) 1999-09-14 2005-11-01 Altana Pharma Ag Tryptase inhibitors
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
CA2392127A1 (en) * 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
ES2222259T3 (es) * 1999-12-20 2005-02-01 Altana Pharma Ag Inhibidores de triptasa.
US7736875B2 (en) * 2000-09-08 2010-06-15 Prozymex A/S Dipeptidyl peptidase I crystal structure and its uses
EP1358182B1 (de) 2001-01-31 2004-08-11 ALTANA Pharma AG Diazocinderivate und deren verwendung als tryptase inhibitoren
WO2002066430A1 (en) * 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
JP2004518735A (ja) 2001-02-21 2004-06-24 アルタナ　ファルマ　アクチエンゲゼルシャフト トリプターゼインヒビター
US6962941B2 (en) 2001-06-19 2005-11-08 Altana Pharma Ag Tryptase inhibitors
AU2002951912A0 (en) * 2002-10-08 2002-10-24 Unisearch Limited Tryptase polypeptide and uses thereof
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
WO2019185586A1 (en) * 2018-03-26 2019-10-03 Universidad Complutense De Madrid Ligands for enhanced imaging and drug delivery to neuroblastoma cells
CN118141793A (zh) * 2022-05-17 2024-06-07 中国医学科学院基础医学研究所 二甲双胍及其它含胍化合物溶解夏科-莱登结晶并缓解急性肺损伤炎症中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX3465E (es) * 1960-10-14 1980-09-12 Wander Ltd Wander Ag Wander S Procedimiento para la obtencion de ureas n,n'-difenil
US4746737A (en) * 1985-07-26 1988-05-24 Kowa Co., Ltd. Phenyl guanidinobenzoate derivatives which have protease inhibitory activity
EP0503203A1 (de) * 1991-03-15 1992-09-16 Merrell Dow Pharmaceuticals Inc. Neue Thrombin-Inhibitoren
CA2100640A1 (en) * 1992-07-23 1994-01-24 Shigeru Matsutani Substitute benzoate derivatives
SK282537B6 (sk) * 1993-03-12 2002-10-08 Axys Pharmaceuticals, Inc. Inhibítor tryptázy alebo jeho farmaceuticky prijateľná soľ, farmaceutický prostriedok s jeho obsahom a jeho použitie
DE4316922A1 (de) * 1993-05-20 1994-11-24 Boehringer Mannheim Gmbh Neue 4-Amidinophenylsulfonamide - Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP0763016A1 (de) 1997-03-19
EP0763016B1 (de) 2000-01-26
US5656660A (en) 1997-08-12
DE69514798D1 (de) 2000-03-02
AU2764495A (en) 1995-12-21
JPH10501238A (ja) 1998-02-03
WO1995032945A1 (en) 1995-12-07

Similar Documents

Publication Publication Date Title
DE69514798D1 (de) Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten
EA200100815A1 (ru) Пептидильные гетероциклические кетоны, применимые в качестве ингибиторов триптазы
MX9702125A (es) Composiciones y metodos para tratar condiciones inflamatorias mediadas por mastocitos.
DE69818049D1 (de) Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
EA200400595A1 (ru) Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы
ATE255090T1 (de) Acylpyrroldicarbonsäuren und acylindoldicarbonsäuren sowie ihre derivate als hemmstoffe der cytosolischen phospholipase a2
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
PT828736E (pt) Heterociclicos sulfonilfenilicos como inibidores de ciclooxigenase-2 e de 5-lipoxigenase
DE60220422D1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
DE69525847D1 (de) Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
ATE234117T1 (de) Verwendung des sekretorischen leukozytaren protease inhibitors (slpi) als tryptase-inhibitor
ATE261932T1 (de) Inhibitoren der alpha-4 beta-1 vermittelten zelladhäsion
ATE457177T1 (de) Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe
WO2001092253A3 (en) Inhibitors of alpha l beta 2 mediated cell adhesion
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
LV12495A (en) Compounds and compositions for treating diseases associated with serine protease particularly tryptase activity
DE60129221D1 (de) Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten
ATE317268T1 (de) Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69838002D1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
DE60115237D1 (de) Praziquantel zusammensetzungen zur behandlung von krankheiten verursacht durch kokzidien
DE60045445D1 (de) Verfahren und zusammensetzung zur behandlung von entzündungsreaktion bedingten nasen- und nebenhölenkrankheiten in säugetieren
ATE355287T1 (de) 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
SE9901273D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties